European Commission expands approval of Bristol Myers Squibb’s Reblozyl (luspatercept) to include first-line treatment of transfusion-dependent anaemia in adults with lower-risk myelodysplastic syndromes


2 April 2024 - Approval of Reblozyl is based on head-to-head, pivotal Phase 3 COMMANDS study, in which Reblozyl nearly doubled the percentage of patients achieving transfusion independence and haemoglobin increase, along with increased durability compared to epoetin alfa.

Bristol Myers Squibb today announced that the European Commission has expanded approval of Reblozyl (luspatercept) to include the first-line treatment of adult patients with transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes.

Read BMS press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Medicine , Europe